Patent · US Active

2,4-pyrimidinediamine compounds for treatment of inflammatory disorders

US8334297B2 · kind B2 · utility

5Cited by

1References

26Claims

0Family size

Assignee

Rigel Pharmaceuticals, Inc. · US

Inventors

Hui Li · Santa Clara, US
Esteban Masuda · Menlo Park, US
Stephanie Yung · San Francisco, US
Taisei Kinoshita · San Mateo, US
Rongxian Ding · San Francisco, US
Rajinder Singh · Belmont, US
Tarikere Gururaja · Santa Clara, US
Donald Payan · Hillsborough, US
Kin Tso · San Francisco, US

Key dates

Filing date	Jan 13, 2010
Grant date	Dec 18, 2012
Priority date	—
Expiry date	Oct 15, 2030

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

2,4-Pyrimidinediamine compounds represented by formula (I), methods for preparing the same and methods for treating an inflammatory disorder and for inhibiting the production of IL-23 and/or stimulating the production of IL-10 using the same:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.